CARDURA XL (doxazosin mesylate extended release tablets) is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH).

CARDURA XL (doxazosin mesylate extended release tablets) is not indicated for the treatment of hypertension.

The initial dose of CARDURA XL (doxazosin mesylate extended release tablets) , 4 mg given once daily, should be administered with breakfast. Depending on the patient's symptomatic response and tolerability, the dose may be increased to 8 mg, the maximum recommended dose. The recommended titration interval is 3–4 weeks. If CARDURA XL (doxazosin mesylate extended release tablets) administration is discontinued for several days, therapy should be restarted using the 4 mg once daily dose. Tablets should be swallowed whole, and must not be chewed, divided, cut, or crushed.

If switching from CARDURA to CARDURA XL (doxazosin mesylate extended release tablets) , therapy should be initiated with the lowest dose (4 mg once daily). Prior to starting therapy with CARDURA XL (doxazosin mesylate extended release tablets) , the final evening dose of CARDURA should not be taken.

Concomitant administration of CARDURA XL (doxazosin mesylate extended release tablets) with a PDE-5 inhibitor can result in additive blood pressure lowering effects and symptomatic hypotension; therefore, PDE-5 inhibitor therapy should be initiated at the lowest dose in patients taking CARDURA XL.

CARDURA® XL (doxazosin mesylate extended release tablets) is available as 4 mg (white, imprinted with CXL 4) and 8 mg (white, imprinted with CXL 8) tablets.

Bottle of 30: 4 mg (NDC 0049-2710-30)
Bottle of 30: 8 mg (NDC 0049-2720-30)

Recommended Storage: Store at 25°C (77°F); excursions permitted to 15-30°C (59-86°F) [see USP Controlled Room Temperature].

Distributed by: Roerig, Division of Pfizer Inc, NY, NY 10017. Revised July 2009

Last reviewed on RxList: 4/1/2010
This monograph has been modified to include the generic and brand name in many instances.